Moczygemba Awarded PhRMA Foundation Grant for Sleep Tracking Research

A woman wearing a necklace and smiling.
December 7, 2023
Professor of Health Outcomes Dr. Leticia Moczygemba was awarded a planning grant to test and validate wearable sleep tracking sensors to improve health outcomes for people experiencing homelessness (PEH).

Moczygemba and Janzen Earn Promotions

Two women smiling while both wear dark clothing.
February 27, 2023
Two of the college's distinguished faculty in the Division of Health Outcomes and Division of Pharmacy Practice were recommended for promotion by President Hartzell due to their outstanding accomplishments in research, outreach and education. Dr. Tish Moczygemba will assume the rank of professor and Dr. Kristin Janzen will become a clinical associate professor.

PharmE3D Labs Receive R01 Grant for Complex Vaccine Technologies

Three people smiling.
September 24, 2021
The College of Pharmacy’s Pharmaceutical Engineering and 3D Printing (PharmE3D) Labs recently earned a three-year $1.5 million National Institutes of Health (NIH) R01 grant to research novel manufacturing technology for complex vaccine formulations for influenza and other emerging infectious diseases.

Maniruzzaman Lab Earns Grant to Research 3D Printed COVID-19 Treatment

A man holding up a dish in a lab.
May 26, 2021
The UT College of Pharmacy’s Pharmaceutical Engineering and 3D Printing (PharmE3D) Lab earned a Texas Global Faculty Research Seed Grant for its work on patient-specific treatment of COVID-19.

Improving Health Outcomes for People Experiencing Homelessness is Focus of New Study

Five people holding cell phones and wearing masks.
April 30, 2021
Combining mobile health technology, or mHealth, and community outreach to improve the health outcomes of people experiencing homelessness is the target of a new study led by Division of Health Outcomes Associate Professor Leticia Moczygemba, Pharm.D., Ph.D., thanks to a five-year research grant from the U.S. Department of Health and Human Services Agency for Healthcare Research and Quality.

TxCORE Research Wins PhRMA Foundation Award

Three people smiling.
April 1, 2021
Three researchers from the College of Pharmacy won an award from the Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation. Leticia R. Moczygemba, Pharm.D., Ph.D., Carolyn M. Brown, Ph.D. and Michael Johnsrud, Ph.D., R.Ph. were awarded $5,000 from the PhRMA Foundation for their proposal to advance racial and ethnic representation in value assessments.

Nixon and Hill Earn Faculty Promotions

A woman smiling and a man wearing glasses.
March 24, 2021
Two of the College of Pharmacy’s distinguished faculty were recently promoted due to their outstanding accomplishments in research, outreach and education. Dr. Kimberly Nixon of the Division of Pharmacology and Toxicology will assume the rank of professor and Dr. Lucas G. Hill of the Division of Pharmacy Practice will become a clinical associate professor.

Suh and PharmE3D Labs Win Fellowships for 3D Bioprinting Research

A woman smiling in front of a sign that says "Pharmacy."
March 18, 2021
Student pharmacist Johana Suh earned an undergraduate fellowship award for research on 3D bioprinted modeling of the neurodegenerative disease NPC-1, or Niemann-Pick disease type C1. Suh is a second-year Doctor of Pharmacy candidate in the UT College of Pharmacy, and serves as an undergraduate researcher in the Pharmaceutical Engineering and 3D Printing (PharmE3D) Labs led by Mo Maniruzzaman, Ph.D.

Inhaled Niclosamide a Potential Effective Antiviral to Treat COVID-19

An infrared image of nasal spray being administered.
September 29, 2020
Researchers in the lab of Dr. Hugh D.C. Smyth have released promising results of a new method to treat SARS-CoV-2, the coronavirus that causes COVID-19. The antiviral niclosamide, when incorporated with human lysozyme as a carrier molecule, shows potential as an effective COVID-19 treatment when delivered directly to the airways.

Live Subject Testing Shows Promising Delivery Method for COVID-19 Antiviral Treatment

A microscopic image.
September 23, 2020
Live subject testing results from the Williams Lab show that dry powder inhalation could be a potent and effective delivery method of the antiviral remdesivir to treat patients affected by COVID-19.